Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 37,263 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 37,263 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $15.19, for a total value of $566,024.97. Following the transaction, the chief executive officer directly owned 2,180,518 shares in the company, valued at $33,122,068.42. This trade represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Up 8.2%

Shares of Adaptive Biotechnologies stock traded up $1.13 during trading on Wednesday, hitting $14.84. The stock had a trading volume of 2,188,850 shares, compared to its average volume of 2,046,190. The company has a market capitalization of $2.29 billion, a PE ratio of -37.10 and a beta of 2.29. Adaptive Biotechnologies Corporation has a 1 year low of $6.77 and a 1 year high of $20.76. The stock has a 50 day simple moving average of $15.17 and a 200 day simple moving average of $15.98.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.23) EPS. As a group, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently made changes to their positions in ADPT. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at about $28,000. Sound Income Strategies LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter valued at about $30,000. EverSource Wealth Advisors LLC raised its holdings in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the period. Assetmark Inc. lifted its position in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $51,000. Institutional investors own 99.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ADPT shares. Guggenheim boosted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Finally, BTIG Research lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.